Fulcrum Therapeutics, Inc.
Public company- Headquarters
- CAMBRIDGE, Massachusetts
- Ticker
- FULC
- CIK
- 0001680581
WARN notices since 2024
Workers affected since 2024
Executive changes, last 12 months
Last event
Workers affected over time
Cumulative workers in WARN notices since 2024
Not enough notices to chart yet.
Leadership
| Role and person | Since | Change |
|---|---|---|
| Vice President, Finance and principal accounting officerGreg Tourangeau | Aug 10, 2026 | Departed |
| principal accounting officerAlan Musso | Aug 10, 2026 | Appointed |
Related companies
Same industry and state, with recent events.
- ENANTA PHARMACEUTICALS INC
CEO departs: Jay R. Luly, Ph.D.
- VERTEX PHARMACEUTICALS INC / MA
new member of the board of directors appointed: Daniel Brennan
- Ernexa Therapeutics Inc.
member of the Board appointed: Robert J. Spiegel, M.D.
- BRISTOL MYERS SQUIBB CO
WARN notice: Princeton, NJ
- Executive departure
Vice President, Finance and principal accounting officer departs: Greg Tourangeau
Greg Tourangeau, Vice President, Finance and principal accounting officer of Fulcrum Therapeutics, Inc., departs the role, effective August 7, 2026. The company reported the change in an 8-K that cites Item 5.02.
Source: SEC 8-K, filed Aug 10, 2026Role: Vice President, Finance and principal accounting officer
- Executive appointment
principal accounting officer appointed: Alan Musso
Alan Musso was named principal accounting officer of Fulcrum Therapeutics, Inc., effective August 7, 2026. Alan Musso succeeds Greg Tourangeau. The company reported the change in an 8-K that cites Item 5.02.
Source: SEC 8-K, filed Aug 10, 2026Role: principal accounting officer
Last verified Nov 8, 2026